Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869259/
https://ncbi.nlm.nih.gov/pubmed/27174596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms11579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados